Citation:Sandru A, Panaitescu E, Voinea S, Bolovan M, Stanciu A, Cinca S, et al 2014

Citation

Sandru A, Panaitescu E, Voinea S, Bolovan M, Stanciu A, Cinca S, et al. Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. J Skin Cancer 2014;2014:843214 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25045539.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Sandru A, Panaitescu E, Voinea S, Bolovan M, Stanciu A, Cinca S, et al 2014	What investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic stage I and stage II patients?	Lani Teddy	completed
Sandru A, Panaitescu E, Voinea S, Bolovan M, Stanciu A, Cinca S, et al 2014 2	What investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic stage I and stage II patients?	Tamsin Parrish	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic Stage I and II patients?|]] (compare critical appraisals)
• [[Clinical question:What investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic Stage I and II patients?|]] (compare critical appraisals)

Cited by

1. What investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic stage I and stage II patients?